ProreoCuratisPerson

About

2002: CURATIS was founded as PROREO PHARMA by Günter Graubach and Rudolf Syz. Since then the company has quickly built-up a sizeable portfolio of interesting specialist products and has grown rapidly.

2003: Acquired the rights to Terlipressin (trademark: Haemopressin®) for the treatment of esophageal varices bleeding and hepatorenal syndrome.

2003-2006: Further developed Terlipressin and significantly build-up the business. Today, Terlipressin is successfully registered and marketed in many countries in Europe and Asia as well as in Australia under the trademarks of Haemopressin®, Variquel® or Lucassin®. In the USA, the product is in late stage development.

2005: Incorporated Proreo Pharma SARL to register and market Haemopressin® and several other pharmaceutical products in France.

2006: Speciality European Pharma Ltd, a UK based pharmaceutical company financially backed by Advent Ventures acquired worldwide rights to Terlipressin by acquiring Proreo Pharma International AG, PROREO PHARMA’s international business entity, as well as Proreo Pharma SARL, France.

2007: Established Proreo Pharma Innovation AG, Switzerland to develop and commercialise several products for rare and specialty care diseases.

2009: Proreo Pharma GmbH is set up to market and distribute pharmaceutical products in Germany.

2011: Established Ygraine Therapeutics Ltd, UK to develop a novel treatment for severe aura migraine and various other projects.

2012: Roland Rutschmann replaced Günter Graubach as Chief Executive Officer of PROREO PHARMA and became a shareholder of the company. Roland has a proven track record in pharmaceuticals for Rare Diseases and Specialty Care Diseases following his senior commercial management positions at Actelion and Orphan Europe. Günter now serves as Chairman.

2013: Orphan Pharma Latin America S.A., Uruguay, is established to provide access to effective medicines  for Latin American patients with rare medical conditions.

2014: Reorganised businesses and created two separate entities to focus activities: Proreo Pharma Innovation AG and Curatis AG. All marketed international products are with Proreo Pharma Innovation AG. All marketed products for Switzerland and all development projects are with Curatis AG.

Board

Günter Graubach - Founder & Chairman

Previously CURATIS's Chief Executive Officer, held various commercial management positions at Speciality European Pharma, MyoContract (now Santhera Pharmaceuticals) and Hoffmann-La Roche in Europe, USA, and Latin America; graduated with a Master Degree in Business from the University of Lyon, France and a post graduate degree in Economics from the University of Constance, Germany.

Dr. Roland Rutschmann - Chief Executive Officer

Previously Vice President/General Manager at Orphan Europe in Paris (France), Regional Vice President/General Manager and Vice President Strategic Marketing Europe at Actelion. Worked for Hoffmann-La Roche and Warner-Lambert in Switzerland, The Netherlands and Germany in various managerial marketing and sales positions. Holds a PhD in Cell Biology/Immunology from the University of Basel. Attained commercial education at INSEAD and is Alumni of the INSEAD AMP.

Team

Dr. Roland Rutschmann - Chief Executive Officer

Previously Vice President/General Manager at Orphan Europe in Paris (France), Regional Vice President/General Manager and Vice President Strategic Marketing Europe at Actelion. Worked for Hoffmann-La Roche and Warner-Lambert in Switzerland, The Netherlands and Germany in various managerial marketing and sales positions. Holds a PhD in Cell Biology/Immunology from the University of Basel. Attained commercial education at INSEAD and is Alumni of the INSEAD AMP.

Beat Hermann - Chief Financial Officer

Held several executive positions in financial management and consulting. He has in-depth experience in controlling, corporate finance including VC/start-up, M&A, financing operations and investor communication. In the life sciences sector Beat Hermann had exposure to both, the medical devices and the bio-pharma sectors. He was working for Synthes-Stratec, Chemspeed, New Medical Technologies and Inventive Capital. Holds a degree in economics and business administration from the University of Basel. 

Prof. Klaus Kutz, M.D. - Chief Development Officer

Over ten years of experience as independent consultant in early clinical development for pharmaceutical companies and clinical research organizations. More than 12 years experience as Head of Clinical Pharmacology with world-wide responsibilities for Phase I and Clinical Pharmacokinetics at Sandoz Pharma Ltd and Sanofi Research. A specialist for Internal Medicine, Gastroenterology, and Clinical Pharmacology, he is also Professor of Medicine at the University of Bonn, Germany.

Advisors

Prof. Klaus D. Döhler, Ph.D

Founder and Managing Director of Curatis Pharma GmbH, Hannover, Germany; previously commercial and R&D management positions at various German biotech and pharmaceutical companies; research in endocrinology at Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany, University School of Medicine, Hannover, Germany and University of California Brain Research Institute, Los Angeles, USA; holds a B.A. in Psychology and a M.A. in Biology from California State University, Fresno, USA and a Ph.D. from the University of Göttingen, Germany.

Dr. Herman Kempen

Head of research and drug discovery teams in the area of lipids and atherosclerosis for 18 years, published 90 papers and several patents. Gaubius Institute TNO, Leiden, member of the institute’s Management Team and leader of the Lipid and Atherosclerosis Group. Recruited to head up the Biology Department Metabolic Diseases Research at F. Hoffmann-La Roche in Basel. Broad business development and licensing experience and extensive network in the cardiovascular field (Roche, Speedel, LODH, ultreia).

Prof. Jes Olesen, M.D.

Professor of Neurology at University of Copenhagen and former chief of Danish Headache Center at the Department of Neurology, Glostrup University Hospital. One of the most recognized leading headache researchers in the world and instrumental in developing the standards of Headache Classification: Professor Olesen is the chairman of the classification committee. He led the first trials for triptans, NOS inhibitors and CGRP antagonists in migraine. Professor Olesen chairs a large research group with major projects in most areas of headache research. Other research interests include SPECT studies of cerebral blood flow and transcranial doppler studies, focusing on the pharmacology of the cerebral circulation. Professor Olesen has received many national and international prizes including honorary doctorates e.g. the University of Rome (2001). Leadership positions in numerous scientific societies, including President of International Headache Society (1993-1995), European Federation of Neurological Societies( 1995-2001) and European Brain Council (2000). Honorary member of the Austrian-, French- and British Neurological Societies, as well as a fellow of the Royal College of Physicians. Has authored or co-authored more than 500 papers and book chapters, and has edited or written more than 20 books, most recently The Classification and Diagnosis of Headache Disorders.

Prof. Arnim Pause, M.Sc., Ph.D.

Canada Research Chair for Molecular Oncology at Goodman Cancer Research Center and Department of Biochemistry, McGill University, Montreal, Canada; scientific advisor and consultant for pharmaceutical and biotechnology companies; previously held Research and Development management positions at Boehringer Ingelheim and Max-Plank Institute for Biochemistry, Martinsried, Germany; graduated with a M.Sc. Degree in Molecular Biology from the University of Constance, Germany, followed by a Ph.D. Degree in Biochemistry from McGill University and a postdoctoral fellowship at the National Institutes of Health, USA.